A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Perampanel (Primary) ; Antiepileptic drugs
- Indications Epilepsy; Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 18 Jan 2019 Planned primary completion date changed from 31 Jan 2020 to 1 Jan 2020.
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 04 Dec 2018 New trial record